Cancer Research and Treatment

Original Articles

Presence of RB1 or Absence of LRP1B Mutation Predicts Poor Overall Survival in Patients with Gastric Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma: In Hye Song, Bokyung Ahn, Young Soo Park, Deok Hoon Kim, Seung-Mo Hong; Received July 19, 2024 Accepted September 25, 2024 Published online September 27, 2024; DOI: https://doi.org/10.4143/crt.2024.667 [Accepted]

Abstract PDF: Purpose
Neuroendocrine carcinomas (NECs) of the stomach are extremely rare, but fatal. However, our understanding of the genetic alterations in gastric NECs is limited. We aimed to evaluate genomic and clinicopathological characteristics of gastric NECs and mixed adenoneuroendocrine carcinomas (MANECs).
Materials and Methods
Fourteen gastric NECs, 3 gastric MANECs, and 1381 gastric adenocarcinomas were retrieved from the departmental next-generation sequencing database between 2017 and 2019. Clinicopathological parameters and next-generation sequencing test results were retrospectively collected and reviewed.
Results
Gastric NECs and MANECs frequently harbored alterations of TP53, RB1, SMARCA4, RICTOR, APC, TOP1, SLX4, EGFR, BRCA2, and TERT. In contrast, gastric adenocarcinomas exhibited alterations of TP53, CDH1, LRP1B, ARID1A, ERBB2, GNAS, CCNE1, NOTCH, and MYC. Mutations of AKT3, RB1, and SLX4; amplification of BRCA2 and RICTOR; and deletion of ADAMTS18, DDX11, KLRC3, KRAS, MAX, NFKBIA, NUDT7, and RB1 were significantly more frequent in gastric NECs and MANECs than in gastric adenocarcinomas. The presence of LRP1B mutation was significantly associated with longer overall survival (OS), whereas RB1 mutation and advanced TNM stage were associated with shorter OS.
Conclusion
We identified frequently mutated genes and potential predictors of survival in patients with gastric NECs and MANECs.

547 View
50 Download

Gastrointestinal cancer

The Persistence of Hypertriglyceridemia and the Risk of Early Onset Colorectal Cancer According to Tumor Subsites: A Nationwide Population-Based Study: Young Hoon Chang, Cheol Min Shin, Kyungdo Han, Jin Hyung Jung, Eun Hyo Jin, Joo Hyun Lim, Seung Joo Kang, Yoon Jin Choi, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee; Cancer Res Treat. 2024;56(3):825-837. Published online December 20, 2023; DOI: https://doi.org/10.4143/crt.2023.753

Abstract PDF Supplementary Material PubReader ePub

Purpose
The incidence of early-onset colorectal cancer (EoCRC) is increasing worldwide. The association between hypertriglyceridemia (HTG) and EoCRC risk remains unclear.
Materials and Methods
We conducted a nationwide cohort study of 3,340,635 individuals aged 20-49 years who underwent health checkups between 2009 and 2011 under the Korean National Health Insurance Service. HTG was defined as serum triglyceride (TG) level ≥ 150 mg/dL. According to the change in TG status, participants were categorized into persistent normotriglyceridemia (NTG; group 1), NTG to HTG (group 2), HTG to NTG (group 3), and persistent HTG (group 4) groups. The EoCRC incidence was followed up until 2019.
Results
In total, 7,492 EoCRC cases developed after a mean of 6.05 years of follow-up. Group 4 had the highest risk of EoCRC (adjusted hazard ratio [aHR], 1.097; 95% confidence interval [CI], 1.025 to 1.174). While the risk of rectal cancer was significantly increased in groups 3 and 4 (aHR [95% CI], 1.236 [1.076 to 1.419] and 1.175 [1.042-1.325], respectively), no significant risk differences were observed in right colon cancer. In group 4, male sex and diabetes were associated with a further increased risk of EoCRC (aHR [95% CI], 1.149 [1.082 to 1.221] and 1.409 [1.169 to 1.699], respectively). In addition, there was a dose-response relationship between serum TG levels and the risk of EoCRC (p for trends < 0.0001).
Conclusion
Persistent HTG increased the risk of EoCRC, which was significantly higher only for rectal cancer and marginally higher for other colonic subsites.

Citations

Citations to this article as recorded by

Obesity-Associated Colorectal Cancer
Lucia Gonzalez-Gutierrez, Omar Motiño, Daniel Barriuso, Juan de la Puente-Aldea, Lucia Alvarez-Frutos, Guido Kroemer, Roberto Palacios-Ramirez, Laura Senovilla
International Journal of Molecular Sciences.2024; 25(16): 8836. CrossRef

3,136 View
111 Download
1 Web of Science
1 Crossref

GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-assessment for Initially HER2-Negative Advanced Gastric Cancer Patients after Progression on First-Line Treatment: Jaewon Hyung, Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Meesun Moon, Yoon-Koo Kang; Cancer Res Treat. 2024;56(1):199-207. Published online June 20, 2023; DOI: https://doi.org/10.4143/crt.2023.490

Abstract PDF Supplementary Material PubReader ePub: Purpose
Heterogeneous human epidermal growth factor receptor 2 (HER2) overexpression in gastric cancer may lead to a misdiagnosis of HER2 status. Accurate assessment of HER2 status is essential for optimal treatment as novel HER2-directed agents are being investigated in various clinical settings. We evaluated the usefulness of HER2 re-assessment following progression on first-line treatment in initially HER2-negative advanced gastric cancer (AGC) patients.
Materials and Methods
We enrolled 177 patients with baseline HER2-negative AGC and performed HER2 re-assessment after progression on first-line treatment from February 2012 to June 2016 at Asan Medical Center, Seoul, Korea. The re-assessed HER2 status was analyzed with baseline HER2 status and clinical characteristics.
Results
The median age was 54 years (range, 24 to 80 years), and 123 patients (69.5%) were men. Seven patients (4.0%) were HER2-positive on the re-assessment. Patients with baseline HER2 negativity confirmed by a single test (n=100) had a higher HER2-positive re-assessment rate compared to those who had repeated baseline testing (n=77) (5.0% vs. 2.6%). Among the patients with single baseline HER2 testing, the rate was higher in patients with baseline HER2 immunohistochemistry (IHC) 1+ compared to those with IHC 0 (13.4% vs. 3.6%).
Conclusion
Overall, 4.0% of patients with baseline HER2-negative AGC were HER2-positive on re-assessment, and the HER2-positive re-assessment rate was higher among patients who had a single test at baseline. HER2 re assessment may be considered for initially HER2-negative patients to determine their eligibility for HER2-directed therapy, particularly if their HER2 negativity was determined by a single test, especially if they had a single baseline HER2 IHC 1+ test.

3,270 View
194 Download

Development and Validation of Models to Predict Lymph Node Metastasis in Early Gastric Cancer Using Logistic Regression and Gradient Boosting Machine Methods: Hae Dong Lee, Kyung Han Nam, Cheol Min Shin, Hye Seung Lee, Young Hoon Chang, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sang-Hoon Ahn, Hyung-Ho Kim; Cancer Res Treat. 2023;55(4):1240-1249. Published online March 21, 2023; DOI: https://doi.org/10.4143/crt.2022.1330

Abstract PDF Supplementary Material PubReader ePub

Purpose
To identify important features of lymph node metastasis (LNM) and develop a prediction model for early gastric cancer (EGC) using a gradient boosting machine (GBM) method.
Materials and Methods
The clinicopathologic data of 2556 patients with EGC who underwent gastrectomy were used as training set and the internal validation set (set 1) at a ratio of 8:2. Additionally, 548 patients with EGC who underwent endoscopic submucosal dissection (ESD) as the initial treatment were included in the external validation set (set 2). The GBM model was constructed, and its performance was compared with that of the Japanese guidelines.
Results
LNM was identified in 12.6% (321/2556) of the gastrectomy group (training set & set 1) and 4.3% (24/548) of the ESD group (set 2). In the GBM analysis, the top five features that most affected LNM were lymphovascular invasion, depth, differentiation, size, and location. The accuracy, sensitivity, specificity, and the area under the receiver operating characteristics of set 1 were 0.566, 0.922, 0.516, and 0.867, while those of set 2 were 0.810, 0.958, 0.803, and 0.944, respectively. When the sensitivity of GBM was adjusted to that of Japanese guidelines (beyond the expanded criteria in set 1 [0.922] and eCuraC-2 in set 2 [0.958]), the specificities of GBM in sets 1 and 2 were 0.516 (95% confidence interval, 0.502-0.523) and 0.803 (0.795-0.805), while those of the Japanese guidelines were 0.502 (0.488-0.509) and 0.788 (0.780-0.790), respectively.
Conclusion
The GBM model showed good performance comparable with the eCura system in predicting LNM risk in EGCs.

Citations

Citations to this article as recorded by

Intratumoural and peritumoural CT-based radiomics for diagnosing lepidic-predominant adenocarcinoma in patients with pure ground-glass nodules: a machine learning approach
Y. Zou, Q. Mao, Z. Zhao, X. Zhou, Y. Pan, Z. Zuo, W. Zhang
Clinical Radiology.2024; 79(2): e211. CrossRef
eCura and W-eCura: different scores, different populations, same goal
Rui Morais, Diogo Libanio, João Santos-Antunes
Gut.2024; 73(11): e29. CrossRef
A machine learning model for predicting the lymph node metastasis of early gastric cancer not meeting the endoscopic curability criteria
Minoru Kato, Yoshito Hayashi, Ryotaro Uema, Takashi Kanesaka, Shinjiro Yamaguchi, Akira Maekawa, Takuya Yamada, Masashi Yamamoto, Shinji Kitamura, Takuya Inoue, Shunsuke Yamamoto, Takashi Kizu, Risato Takeda, Hideharu Ogiyama, Katsumi Yamamoto, Kenji Aoi,
Gastric Cancer.2024; 27(5): 1069. CrossRef
The Application of Artificial Intelligence to Cancer Research: A Comprehensive Guide
Amin Zadeh Shirazi, Morteza Tofighi, Alireza Gharavi, Guillermo A. Gomez
Technology in Cancer Research & Treatment.2024;[Epub] CrossRef
Computed Tomography-Based Radiomics Analysis of Different Machine Learning Approaches for Differentiating Pulmonary Sarcomatoid Carcinoma and Pulmonary Inflammatory Pseudotumor
An-Lin Zhang, Yan-Mei Fu, Zhi-Yang He
Iranian Journal of Radiology.2024;[Epub] CrossRef
Screening of gastric cancer diagnostic biomarkers in the homologous recombination signaling pathway and assessment of their clinical and radiomic correlations
Ahao Wu, Tengcheng Hu, Chao Lai, Qingwen Zeng, Lianghua Luo, Xufeng Shu, Pan Huang, Zhonghao Wang, Zongfeng Feng, Yanyan Zhu, Yi Cao, Zhengrong Li
Cancer Medicine.2024;[Epub] CrossRef

5,009 View
214 Download
7 Web of Science
6 Crossref

Aberrant DNA Methylation Maker for Predicting Metachronous Recurrence After Endoscopic Resection of Gastric Neoplasms: Cheol Min Shin, Nayoung Kim, Hyuk Yoon, Yoon Jin Choi, Ji Hyun Park, Young Soo Park, Dong Ho Lee; Cancer Res Treat. 2022;54(4):1157-1166. Published online January 18, 2022; DOI: https://doi.org/10.4143/crt.2021.997

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate whether MOS methylation can be useful for the prediction of metachronous recurrence after endoscopic resection of gastric neoplasms.
Materials and Methods
From 2012 to 2017, 294 patients were prospectively enrolled after endoscopic resection of gastric dysplasia (n=171) or early gastric cancer (n=123). When Helicobacter pylori was positive, eradication therapy was performed. Among them, 124 patients completed the study protocol (follow-up duration > 3 years or development of metachronous recurrence during the follow-up). Methylation levels of MOS were measured at baseline using quantitative MethyLight assay from the antrum.
Results
Median follow-up duration was 49.9 months. MOS methylation levels at baseline were not different by age, sex, and current H. pylorii infection, but they showed a weak correlation with operative link on gastritis assessment (OLGA) or operative link on gastric intestinal metaplasia assessment (OLGIM) stages (Spearman’s ρ=0.240 and 0.174, respectively; p < 0.05). During the follow-up, a total of 20 metachronous gastric neoplasms (13 adenomas and 7 adenocarcinomas) were developed. Either OLGA or OLGIM stage was not useful in predicting the risk for metachronous recurrence. In contrast, MOS methylation high group (≥ 34.82%) had a significantly increased risk for metachronous recurrence compared to MOS methylation low group (adjusted hazard ratio, 4.76; 95% confidence interval, 1.54 to 14.79; p=0.007).
Conclusion
MOS methylation can be a promising marker for predicting metachronous recurrence after endoscopic resection of gastric neoplasms. To confirm the usefulness of MOS methylation, validation studies are warranted in the future (ClinicalTrials No. NCT04830618).

Citations

Citations to this article as recorded by

MIR124-3 and NKX6-1 hypermethylation profiles accurately predict metachronous gastric lesions in a Caucasian population
Catarina Lopes, Tatiana C. Almeida, Catarina Macedo-Silva, João Costa, Sofia Paulino, Carmen Jerónimo, Diogo Libânio, Mário Dinis-Ribeiro, Carina Pereira
Clinical Epigenetics.2024;[Epub] CrossRef
The methylation signature of hepatocellular carcinoma trajectory based on pseudotime and chronological time for predicting precancerous patients
Kang Li, Chaoran Zang, Yanan Zhao, Dandan Guo, Wanting Shi, Tingting Mei, Ang Li, Yonghong Zhang
The Oncologist.2024;[Epub] CrossRef
Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study
Yun Suk Na, Sang Gyun Kim, Soo-Jeong Cho
Gastric Cancer.2023; 26(2): 298. CrossRef

5,606 View
142 Download
5 Web of Science
3 Crossref

Association between the Persistence of Obesity and the Risk of Gastric Cancer: A Nationwide Population-Based Study: Joo Hyun Lim, Cheol Min Shin, Kyung-Do Han, Seung Woo Lee, Eun Hyo Jin, Yoon Jin Choi, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee; Cancer Res Treat. 2022;54(1):199-207. Published online May 4, 2021; DOI: https://doi.org/10.4143/crt.2021.130

Abstract PDF Supplementary Material PubReader ePub

Purpose
There remains controversy about relationship between obesity and gastric cancer. We aimed to examine the association using obesity-persistence.
Materials and Methods
We analyzed a nationwide population-based cohort which underwent health check-up between 2009 and 2012. Among them, those who had annual examinations during the last 5 years were selected. Gastric cancer risk was compared between those without obesity during the 5 years (never-obesity group) and those with obesity diagnosis during the 5 years (non-persistent obesity group; persistent obesity group).
Results
Among 2,757,017 individuals, 13,441 developed gastric cancer after median 6.78 years of follow-up. Gastric cancer risk was the highest in persistent obesity group (incidence rate [IR], 0.89/1,000 person-years; hazard ratio [HR], 1.197; 95% confidence interval [CI], 1.117 to 1.284), followed by non-persistent obesity group (IR, 0.83/1,000 person-years; HR, 1.113; 95% CI, 1.056 to 1.172) compared with never-obesity group. In subgroup analysis, this positive relationship was true among those < 65 years old and male. Among heavy-drinkers, the impact of obesity-persistence on the gastric cancer risk far increased (non-persistent obesity: HR, 1.297; 95% CI, 1.094 to 1.538; persistent obesity: HR, 1.351; 95% CI, 1.076 to 1.698).
Conclusion
Obesity-persistence is associated with increased risk of gastric cancer in a dose-response manner, especially among male < 65 years old. The risk raising effect was much stronger among heavy-drinkers.

Citations

Citations to this article as recorded by

Diagnosis of gastric cancer in role of endoscopic imaging techniques in artificial intelligence and machine learning applications: An overview
Pooja K., Kishore Kanna R., G. Li, U. Subramaniam, M. Sekar
E3S Web of Conferences.2024; 491: 03016. CrossRef
Joint association of drinking alcohol and obesity in relation to cancer risk: A systematic review and data synthesis
Graeme A. Macdonald, James A. Thomas, Christine Dalais, Bradley J. Kendall, Aaron P. Thrift
Cancer Epidemiology.2024; 91: 102596. CrossRef
Roles of long non‑coding RNA SNHG16 in human digestive system cancer (Review)
Lujie Zhao, Yuling Kan, Lu Wang, Jiquan Pan, Yun Li, Haiyan Zhu, Zhongfa Yang, Lin Xiao, Xinhua Fu, Fujun Peng, Haipeng Ren
Oncology Reports.2024;[Epub] CrossRef
Adiposity and risks of gastrointestinal cancers: A 10‐year prospective study of 0.5 million Chinese adults
Wing Ching Chan, Iona Millwood, Christiana Kartsonaki, Huaidong Du, Daniel Schmidt, Rebecca Stevens, Junshi Chen, Pei Pei, Canqing Yu, Dianjianyi Sun, Jun Lv, Xianyong Han, Liming Li, Zhengming Chen, Ling Yang
International Journal of Cancer.2024;[Epub] CrossRef
Gastric Cancer Risk in Association with Underweight, Overweight, and Obesity: A Systematic Review and Meta-Analysis
Narges Azizi, Moein Zangiabadian, Golnoosh Seifi, Afshan Davari, Elham Yekekhani, Seyed Amir Ahmad Safavi-Naini, Nathan A. Berger, Mohammad Javad Nasiri, Mohammad-Reza Sohrabi
Cancers.2023; 15(10): 2778. CrossRef
Recent research progress on the correlation between metabolic syndrome and Helicobacter pylori infection
Qinli Xie, Yangjun He, Danni Zhou, Yi Jiang, Ying Deng, Ruoqing Li
PeerJ.2023; 11: e15755. CrossRef
Risk of gastric cancer in relation with serum cholesterol profiles: A nationwide population-based cohort study
Mi Jin Oh, Kyungdo Han, Bongseong Kim, Joo Hyun Lim, Bokyung Kim, Sang Gyun Kim, Soo-Jeong Cho
Medicine.2023; 102(48): e36260. CrossRef
Decreasing Incidence of Gastric Cancer with Increasing Time after Helicobacter pylori Treatment: A Nationwide Population-Based Cohort Study
Taewan Kim, Seung In Seo, Kyung Joo Lee, Chan Hyuk Park, Tae Jun Kim, Jinseob Kim, Woon Geon Shin
Antibiotics.2022; 11(8): 1052. CrossRef
Integration of clinical and transcriptomics reveals programming of the lipid metabolism in gastric cancer
Yanyan Li, Jungang Zhao, Renpin Chen, Shengwei Chen, Yilun Xu, Weiyang Cai
BMC Cancer.2022;[Epub] CrossRef
Body fatness associations with cancer: evidence from recent epidemiological studies and future directions
Susanna C. Larsson, Nikolaos Spyrou, Christos S. Mantzoros
Metabolism.2022; 137: 155326. CrossRef
FOXC2-AS1 stabilizes FOXC2 mRNA via association with NSUN2 in gastric cancer cells
Jijun Yan, Juntao Liu, Zhengbin Huang, Wenwei Huang, Jianfa Lv
Human Cell.2021; 34(6): 1755. CrossRef

7,666 View
253 Download
10 Web of Science
11 Crossref

Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer: Jung Yoon Choi, Sunho Choi, Minhyeok Lee, Young Soo Park, Jae Sook Sung, Won Jin Chang, Ju Won Kim, Yoon Ji Choi, Jin Kim, Dong-Sik Kim, Sung-Ho Lee, Junhee Seok, Kyong Hwa Park, Seon Hahn Kim, Yeul Hong Kim; Cancer Res Treat. 2020;52(3):764-778. Published online February 16, 2020; DOI: https://doi.org/10.4143/crt.2020.044

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to identify the concordant or discordant genomic profiling between primary and matched metastatic tumors in patients with colorectal cancer (CRC) and to explore the clinical implication.
Materials and Methods
Surgical samples of primary and matched metastatic tissues from 158 patients (335 samples) with CRC at Korea University Anam Hospital were evaluated using the Ion AmpliSeq Cancer Hotspot Panel. We compared genetic variants and classified them as concordant, primary-specific, and metastasis-specific variants. We used a combination of principal components analysis and clustering to find genomic groups. Kaplan-Meier curves were used to appraise survival between genomic groups. We used machine learning to confirm the correlation between genetic variants and metastatic sites.
Results
A total of 282 types of deleterious non-synonymous variants were selected for analysis. Of a total of 897 variants, an average of 40% was discordant. Three genomic groups were yielded based on the genomic discrepancy patterns. Overall survival differed significantly between the genomic groups. The poorest group had the highest proportion of concordant KRAS G12V and additional metastasis-specific SMAD4. Correlation analysis between genetic variants and metastatic sites suggested that concordant KRAS mutations would have more disseminated metastases.
Conclusion
Driver gene mutations were mostly concordant; however, discordant or metastasis-specific mutations were present. Clinically, the concordant driver genetic changes with additional metastasis-specific variants can predict poor prognosis for patients with CRC.

Citations

Citations to this article as recorded by

Gene-Mutation-Based Algorithm for Prediction of Treatment Response in Colorectal Cancer Patients
Heather Johnson, Zahra El-Schich, Amjad Ali, Xuhui Zhang, Athanasios Simoulis, Anette Gjörloff Wingren, Jenny L. Persson
Cancers.2022; 14(8): 2045. CrossRef
Putative anoikis resistant subpopulations are enriched in lymph node metastases and indicate adverse prognosis in colorectal carcinoma
Taneli T. Mattila, Madhura Patankar, Juha P. Väyrynen, Kai Klintrup, Jyrki Mäkelä, Anne Tuomisto, Pentti Nieminen, Markus J. Mäkinen, Tuomo J. Karttunen
Clinical & Experimental Metastasis.2022; 39(6): 883. CrossRef
Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project
Youngwoo Lee, Soohyeon Lee, Jae Sook Sung, Hee-Joon Chung, Ah-reum Lim, Ju Won Kim, Yoon Ji Choi, Kyong Hwa Park, Yeul Hong Kim
Cancer Research and Treatment.2021; 53(1): 123. CrossRef
Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status
Zhengquan Xu, Yanhong Ding, Wei Lu, Ke Zhang, Fei Wang, Guanxiong Ding, Jianqing Wang
PeerJ.2021; 9: e11133. CrossRef
High Concordance of Genomic Profiles between Primary and Metastatic Colorectal Cancer
Seung Eun Lee, Ha Young Park, Dae-Yong Hwang, Hye Seung Han
International Journal of Molecular Sciences.2021; 22(11): 5561. CrossRef
Comprehensive Imaging Characterization of Colorectal Liver Metastases
Drew Maclean, Maria Tsakok, Fergus Gleeson, David J. Breen, Robert Goldin, John Primrose, Adrian Harris, James Franklin
Frontiers in Oncology.2021;[Epub] CrossRef

8,387 View
199 Download
6 Web of Science
6 Crossref

Inter-observer Reproducibility in the Pathologic Diagnosis of Gastric Intraepithelial Neoplasia and Early Carcinoma in Endoscopic Submucosal Dissection Specimens: A Multi-center Study: Joon Mee Kim, Jin Hee Sohn, Mee-Yon Cho, Woo Ho Kim, Hee Kyung Chang, Eun Sun Jung, Myeong-Cherl Kook, So-Young Jin, Yang Seok Chae, Young Soo Park, Mi Seon Kang, Hyunki Kim, Jae Hyuk Lee, Do Youn Park, Kyoung Mee Kim, Hoguen Kim, Young Ju Suh, Sang Yong Seol, Hwoon-Yong Jung, Deuck–Hwa Kim, Na Rae Lee, Seung-Hee Park, Ji Hye You; Cancer Res Treat. 2019;51(4):1568-1577. Published online April 1, 2019; DOI: https://doi.org/10.4143/crt.2019.019

Abstract PDF PubReader ePub

Purpose
The diagnostic criteria of gastric intraepithelial neoplasia (IEN) are controversial across the world. We investigated how many discrepancies occur in the pathologic diagnosis of IEN and early gastric carcinoma in endoscopic submucosal dissection (ESD) specimens, and evaluated the reasons of the discordance.
Materials and Methods
We retrospectively reviewed 1,202 ESD specimens that were originally diagnosed as gastric IEN and early carcinoma at 12 institutions.
Results
The final consensus diagnosis of carcinoma were 756 cases, which were originally 692 carcinomas (91.5%), 43 high-grade dysplasias (5.7%), 20 low-grade dysplasias (2.6%), and 1 others (0.1%), respectively. High- and low-grade dysplasia were finally made in 63 and 342 cases, respectively. The diagnostic concordance with the consensus diagnosis was the highest for carcinoma (91.5%), followed by low-grade dysplasia (86.3%), others (63.4%) and high-grade dysplasia (50.8%). The general kappa value was 0.83, indicating excellent concordance. The kappa values of individual institutions ranged from 0.74 to 1 and correlated with the proportion of carcinoma cases. The cases revised to a final diagnosis of carcinoma exhibited both architectural abnormalities and cytologic atypia. The main differential points between low- and high-grade dysplasias were the glandular distribution and glandular shape. Additional features such as the glandular axis, surface maturation, nuclear stratification and nuclear polarity were also important.
Conclusion
The overall concordance of the diagnosis of gastric IEN and early carcinoma in ESD specimens was excellent. It correlated with the proportion of carcinoma cases, demonstrating that the diagnostic criteria for carcinoma are more reproducible than those for dysplasia.

Citations

Citations to this article as recorded by

Seeing the random forest through the decision trees. Supporting learning health systems from histopathology with machine learning models: Challenges and opportunities
Ricardo Gonzalez, Ashirbani Saha, Clinton J.V. Campbell, Peyman Nejat, Cynthia Lokker, Andrew P. Norgan
Journal of Pathology Informatics.2024; 15: 100347. CrossRef
A new, simplified endoscopic scoring system for predicting clinical outcome in gastric low-grade intraepithelial neoplasia: the “e-cout system”
Nanjun Wang, Xiaotong Niu, Longsong Li, Jing Tang, Yawei Bi, Shengzhen Liu, Ke Han, Yaxuan Cheng, Zhaobei Cai, Ningli Chai, Enqiang Linghu
Neoplasia.2024; 56: 101030. CrossRef
A Prediction Model Based on the Risk Factors Associated with Pathological Upgrading in Patients with Early-Stage Gastric Neoplasms Diagnosed by Endoscopic Forceps Biopsy
Yu Han Zhao, Yu Zheng, Jie Sha, Hong Jin Hua, Ke Dong Li, Yu Lu, Yi Ni Dang, Guo Xin Zhang
Gut and Liver.2023; 17(1): 78. CrossRef
A standardized pathology report for gastric cancer: 2nd edition
Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
Journal of Pathology and Translational Medicine.2023; 57(1): 1. CrossRef
Tumor heterogeneity and carcinoma in resected specimens of gastric low-grade dysplasia: A retrospective single center study
Ga-Yeong Shin, Jun Young Park, Sung Hak Lee, Yu Kyung Cho, Myung-Gyu Choi, Jae Myung Park, Alessandro Rizzo
PLOS ONE.2023; 18(1): e0280735. CrossRef
A Standardized Pathology Report for Gastric Cancer: 2nd Edition
Young Soo Park, Myeong-Cherl Kook, Baek-hui Kim, Hye Seung Lee, Dong-Wook Kang, Mi-Jin Gu, Ok Ran Shin, Younghee Choi, Wonae Lee, Hyunki Kim, In Hye Song, Kyoung-Mee Kim, Hee Sung Kim, Guhyun Kang, Do Youn Park, So-Young Jin, Joon Mee Kim, Yoon Jung Choi,
Journal of Gastric Cancer.2023; 23(1): 107. CrossRef
Accuracy of administrative claim data for gastric adenoma after endoscopic resection
Ga-Yeong Shin, Hyun Ho Choi, Jae Myung Park, Sang Yoon Kim, Jun Young Park, Donghoon Kang, Yu Kyung Cho, Sung Soo Kim, Myung-Gyu Choi
Clinical Endoscopy.2023; 56(3): 325. CrossRef
Artificial Intelligence in the Pathology of Gastric Cancer
Sangjoon Choi, Seokhwi Kim
Journal of Gastric Cancer.2023; 23(3): 410. CrossRef
Establishment and validation of a clinical diagnostic model for gastric low-grade intraepithelial neoplasia
Ting Sun, Xi-quan Ke, Meng Wang, Qi-zhi Wang
Medicine.2023; 102(46): e35515. CrossRef
Assessment of deep learning assistance for the pathological diagnosis of gastric cancer
Wei Ba, Shuhao Wang, Meixia Shang, Ziyan Zhang, Huan Wu, Chunkai Yu, Ranran Xing, Wenjuan Wang, Lang Wang, Cancheng Liu, Huaiyin Shi, Zhigang Song
Modern Pathology.2022; 35(9): 1262. CrossRef
Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens
Zhongyue Shi, Chuang Zhu, Yu Zhang, Yakun Wang, Weihua Hou, Xue Li, Jun Lu, Xinmeng Guo, Feng Xu, Xingran Jiang, Ying Wang, Jun Liu, Mulan Jin
Gastric Cancer.2022; 25(4): 751. CrossRef
Documento de posicionamiento de la AEG, la SEED y la SEAP sobre cribado de cáncer gástrico en poblaciones con baja incidencia
Joaquín Cubiella, Ángeles Pérez Aisa, Miriam Cuatrecasas, Pilar Díez Redondo, Gloria Fernández Esparrach, José Carlos Marín-Gabriel, Leticia Moreira, Henar Núñez, M. Luisa Pardo López, Enrique Rodríguez de Santiago, Pedro Rosón, José Miguel Sanz Anquela,
Gastroenterología y Hepatología.2021; 44(1): 67. CrossRef
Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP
Joaquin Cubiella, Ángeles Pérez Aisa, Miriam Cuatrecasas, Pilar Díez Redondo, Gloria Fernández Esparrach, José Carlos Marín-Gabriel, Leticia Moreira, Henar Núñez, M. Luisa Pardo López, Enrique Rodríguez de Santiago, Pedro Rosón, José Miguel Sanz Anquela,
Gastroenterología y Hepatología (English Edition).2021; 44(1): 67. CrossRef

9,326 View
254 Download
12 Web of Science
13 Crossref

APE1/Ref-1 as a Serological Biomarker for the Detection of Bladder Cancer: Ju Hyun Shin, Sunga Choi, Yu Ran Lee, Myoung Soo Park, Yong Gil Na, Kaikobad Irani, Sang Do Lee, Jin Bong Park, Jin Man Kim, Jae Sung Lim, Byeong Hwa Jeon; Cancer Res Treat. 2015;47(4):823-833. Published online January 2, 2015; DOI: https://doi.org/10.4143/crt.2014.074

Abstract PDF PubReader ePub

Purpose
Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) is a multifunctional protein that shows elevated expression in a number of cancers. We attempted to determine whether serum APE1/Ref-1 is elevated in patients with bladder cancer.
Materials and Methods
Serum APE1/Ref-1 levels were determined using enzyme-linked immunosorbent assay in serum from patients with bladder cancer who had not received chemotherapy or radiotherapy (n=51) and non-tumor controls (n=55). The area under the receiver operating characteristic area under the curve was applied to determine the correlation between clinical factors and the serum levels of APE1/Ref-1.
Results
Serum levels of APE1/Ref-1 in bladder cancer patients were significantly elevated compared to those of the control group (3.548±0.333 ng/100 μL [n=51] for bladder cancer vs. 1.547±0.319 ng/100 μL [n=55] for the control group), with a sensitivity and specificity of 93% and 59%, respectively. Serum APE1/Ref-1 levels are associated with tumor stage, grade, muscle invasion, and recurrence.
Conclusion
Serum APE1/Ref-1 might be useful as a potential serologic biomarker for bladder cancer.

Citations

Citations to this article as recorded by

Leveraging CRISPR/Cas12 signal amplifier to sensitive detection of apurinic/apyrimidinic endonuclease 1 and high-throughput inhibitor screening
Sheng Ding, Yi Yuan, Juan Dong, Feng Du, Xin Cui, Zheng Shi, Zhuo Tang
Analytica Chimica Acta.2024; 1291: 342212. CrossRef
Protective effect of secretory APE1/Ref‐1 on doxorubicin‐induced cardiotoxicity via suppression of ROS and p53 pathway
Soo Yeon An, Seon‐Ah Jin, Hee Jeong Seo, Yu Ran Lee, Sungmin Kim, Byeong Hwa Jeon, Jin‐Ok Jeong
ESC Heart Failure.2024; 11(2): 1182. CrossRef
Enhancing APE1 detection through apurinic/apyrimidinic site inhibition of DNA polymerase: an innovative, highly sensitive approach
Zhijun Liu, Bei Yan, Huan Liu, Xiao Liu, Xianjin Xiao, Zhihao Ming
Chemical Communications.2024; 60(35): 4695. CrossRef
The DNA-repair protein APE1 participates with hnRNPA2B1 to motif-enriched and prognostic miRNA secretion
Giovanna Mangiapane, Michela Notarangelo, Giulia Canarutto, Fabrizio Fabbiano, Emiliano Dalla, Monica Degrassi, Giulia Antoniali, Nicolò Gualandi, Veronica De Sanctis, Silvano Piazza, Vito Giuseppe D’Agostino, Gianluca Tell
Oncogene.2024; 43(24): 1861. CrossRef
Dual-driven AND molecular logic gates for label-free and sensitive ratiometric fluorescence sensing and inhibitors screening
Qiongdan Zhang, Qingyi Liu, Gang Fu, Feibing Huang, Yanfu Tang, Yixing Qiu, Anqi Ge, Jinhui Hu, Wei Wang, Bin Li, Huizhen Wang
Journal of Colloid and Interface Science.2024; 674: 841. CrossRef
A recognition-induced three-dimensional bipedal DNA walker for highly sensitive detection of APE1
Qingyi Liu, Qiongdan Zhang, Yuting Zhang, Fanghong Tian, Kang Long, Yupei Yang, Wei Wang, Caiyun Peng, Huizhen Wang
Analytical Methods.2024; 16(36): 6220. CrossRef
Role of APE1 in hepatocellular carcinoma and its prospects as a target in clinical settings (Review)
Lei Yang, Zhipeng Sun
Molecular and Clinical Oncology.2024;[Epub] CrossRef
A multifunctional DNA repair enzyme and magnetic dual-triggered theranostic nanosystem for intelligent drug delivery
Zhuo Peng, Keni Ning, Xiaoyan Tang, Ruikai He, Dong-Yang Zhang, Yan Ma, Shixia Guan, Junqiu Zhai
Materials & Design.2023; 226: 111611. CrossRef
Electrochemical biosensor based on bipedal DNA walker for highly sensitive amplification detection of apurinic/apyrimidinic endonuclease 1
Xingcong Wang, Jinting Meng, Haoping Zhang, Jingyan Mou, Jinping Xiong, Hong Wang, Xin Su, Yingwei Zhang
Sensors and Actuators B: Chemical.2023; 381: 133425. CrossRef
An AND‐Gate DNA Nanodevice for Dual Protein‐Mediated, Tumor‐Specific Imaging
Zetan Fan, Fangzhi Yu, Mingming Yu, Lele Li
Chinese Journal of Chemistry.2023; 41(12): 1437. CrossRef
Revisiting Two Decades of Research Focused on Targeting APE1 for Cancer Therapy: The Pros and Cons
Matilde Clarissa Malfatti, Alessia Bellina, Giulia Antoniali, Gianluca Tell
Cells.2023; 12(14): 1895. CrossRef
Elevated Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Effector Factor-1 Levels in Refractory Kawasaki Disease
Yu-Ran Lee, Eun Young Bae, Hong Ryang Kil, Byeong-Hwa Jeon, Geena Kim
Biomedicines.2022; 10(1): 190. CrossRef
Mechanistic decoupling of exonuclease III multifunctionality into AP endonuclease and exonuclease activities at the single-residue level
Donghun Lee, Sanghoon Oh, HyeokJin Cho, Jungmin Yoo, Gwangrog Lee
Nucleic Acids Research.2022; 50(4): 2211. CrossRef
APE1/Ref-1 Role in Inflammation and Immune Response
Thais Teixeira Oliveira, Leonam Gomes Coutinho, Laysa Ohana Alves de Oliveira, Ana Rafaela de Souza Timoteo, Guilherme Cavalcanti Farias, Lucymara Fassarella Agnez-Lima
Frontiers in Immunology.2022;[Epub] CrossRef
“RESET” Effect: Random Extending Sequences Enhance the Trans-Cleavage Activity of CRISPR/Cas12a
Jia-Yi Ma, Si-Yuan Wang, Yi-Chen Du, Dong-Xia Wang, An-Na Tang, Jing Wang, De-Ming Kong
Analytical Chemistry.2022; 94(22): 8050. CrossRef
A dual-functional fluorescent biosensor based on enzyme-involved catalytic hairpin assembly for the detection of APE1 and miRNA-21
Xiaoyong Lu, Dan Li, Zewei Luo, Yixiang Duan
The Analyst.2022; 147(12): 2834. CrossRef
Incorporating quaternary mesoporous nanospheres and DNA stochastic nanowalkers into a signal amplified switch: A highly sensitive electrochemical assay for APE1
Qingsong Wei, Zhisheng Teng, Xuelian Luo, Yuxin Yang, Yuxia Ren, Wenbin Liang, Ying Zhuo, Zhaoyang Zhong
Sensors and Actuators B: Chemical.2022; 370: 132386. CrossRef
Identification and Quantification of Apurinic/Apyrimidinic Endonuclease 1 in Human Peripheral Blood Leukocytes by Liquid Chromatography/Isotope-Dilution High Resolution Mass Spectrometry
Gamze TUNA
Journal of Basic and Clinical Health Sciences.2022; 6(3): 851. CrossRef
The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease
Rachel A. Caston, Silpa Gampala, Lee Armstrong, Richard A. Messmann, Melissa L. Fishel, Mark R. Kelley
Drug Discovery Today.2021; 26(1): 218. CrossRef
A DNA structure-mediated fluorescent biosensor for apurinic/apyrimidinic endonuclease 1 activity detection with ultra-high sensitivity and selectivity
Yuqiang Hu, Zhen Zhang, Weicong Ye, Wei Zhang, Minghao Hu, Wenqian Yuan, Hongbo Wang, Xianjin Xiao, Tongbo Wu
Sensors and Actuators B: Chemical.2021; 330: 129332. CrossRef
Spectroscopic sensing and quantification of AP-endonucleases using fluorescence-enhancement by cis–trans isomerization of cyanine dyes
JunHo Cho, Sanghoon Oh, DongHun Lee, Jae Won Han, Jungmin Yoo, Daeho Park, Gwangrog Lee
RSC Advances.2021; 11(19): 11380. CrossRef
Enzymatically active apurinic/apyrimidinic endodeoxyribonuclease 1 is released by mammalian cells through exosomes
Giovanna Mangiapane, Isabella Parolini, Kristel Conte, Matilde Clarissa Malfatti, Jessica Corsi, Massimo Sanchez, Agostina Pietrantoni, Vito G. D’Agostino, Gianluca Tell
Journal of Biological Chemistry.2021; 296: 100569. CrossRef
APE1 and SSRP1 is overexpressed in muscle invasive bladder cancer and associated with poor survival
Heyu Song, Jiping Zeng, Subodh Lele, Chad A. LaGrange, Kishor K. Bhakat
Heliyon.2021; 7(4): e06756. CrossRef
Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1α interaction in lung cancer
Asmat Ullah, Sze Wei Leong, Jingjing Wang, Qing Wu, Mohsin Ahmad Ghauri, Ammar Sarwar, Qi Su, Yanmin Zhang
Cell Death & Disease.2021;[Epub] CrossRef
A Cooperatively Activatable, DNA‐based Fluorescent Reporter for Imaging of Correlated Enzymatic Activities
Zetan Fan, Jian Zhao, Xin Chai, Lele Li
Angewandte Chemie.2021; 133(27): 15013. CrossRef
A Cooperatively Activatable, DNA‐based Fluorescent Reporter for Imaging of Correlated Enzymatic Activities
Zetan Fan, Jian Zhao, Xin Chai, Lele Li
Angewandte Chemie International Edition.2021; 60(27): 14887. CrossRef
Blood-based protein biomarkers in bladder urothelial tumors
Rubén López-Cortés, Benito Blanco Gómez, Sergio Vázquez-Estévez, Daniel Pérez-Fentes, Cristina Núñez
Journal of Proteomics.2021; 247: 104329. CrossRef
Changes in the Plasma Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1(APE1/Ref-1) Level during Cancer Surgery: An Observational Study
Yumin Jo, Yeojung Kim, Eunhye Park, Yuran Lee, Jiyeon Kim, Minwoong Kang, Jaesung Lim, Insang Song, Chaeseong Lim, Byeonghwa Jeon
Medicina.2021; 57(11): 1280. CrossRef
Nucleases as molecular targets for cancer diagnosis
Alien Balian, Frank J. Hernandez
Biomarker Research.2021;[Epub] CrossRef
Graphene Quantum Dot-Based Nanocomposites for Diagnosing Cancer Biomarker APE1 in Living Cells
Hao Zhang, Sai Ba, Zhaoqi Yang, Tianxiang Wang, Jasmine Yiqin Lee, Tianhu Li, Fangwei Shao
ACS Applied Materials & Interfaces.2020; 12(12): 13634. CrossRef
The Biological Role of Apurinic/Apyrimidinic Endonuclease1/Redox Factor-1 as a Therapeutic Target for Vascular Inflammation and as a Serologic Biomarker
Yu Ran Lee, Hee Kyoung Joo, Byeong Hwa Jeon
Biomedicines.2020; 8(3): 57. CrossRef
Non-muscle invasive bladder cancer tissues have increased base excision repair capacity
Berna Somuncu, Selcuk Keskin, Fatma Merve Antmen, Yesim Saglican, Aysegul Ekmekcioglu, Tugce Ertuzun, Mustafa Bilal Tuna, Can Obek, David M. Wilson, Umit Ince, Ali Riza Kural, Meltem Muftuoglu
Scientific Reports.2020;[Epub] CrossRef
Correlation of APE1 with VEGFA and CD163+ macrophage infiltration in bladder cancer and their prognostic significance
Lin-Ang Wang, Bo Yang, Tang Tang, Yuxin Yang, Dianzheng Zhang, Hualiang Xiao, Jing Xu, Luofu Wang, Li Lin, Jun Jiang
Oncology Letters.2020; 20(3): 2881. CrossRef
Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Could Serve as a Potential Serological Biomarker for the Diagnosis and Prognosis of Oral Squamous Cell Carcinoma
Jianli Xie, Ying Li, Jingjing Kong, Chong Li
Journal of Oral and Maxillofacial Surgery.2019; 77(4): 859. CrossRef
The extracellular role of Ref-1 as anti-inflammatory function in lipopolysaccharide-induced septic mice
Hee Kyoung Joo, Yu Ran Lee, Eun-Ok Lee, Myoung Soo Park, Sunga Choi, Cuk-Seong Kim, Jin-Bong Park, Byeong Hwa Jeon
Free Radical Biology and Medicine.2019; 139: 16. CrossRef
ATP Binding Cassette Transporter A1 is Involved in Extracellular Secretion of Acetylated APE1/Ref-1
Yu Ran Lee, Hee Kyoung Joo, Eun Ok Lee, Hyun Sil Cho, Sunga Choi, Cuk-Seong Kim, Byeong Hwa Jeon
International Journal of Molecular Sciences.2019; 20(13): 3178. CrossRef
An electrochemical biosensor integrating immunoassay and enzyme activity analysis for accurate detection of active human apurinic/apyrimidinic endonuclease 1
Mengru Zhou, Chang Feng, Dongsheng Mao, Shiqi Yang, Lingjie Ren, Guifang Chen, Xiaoli Zhu
Biosensors and Bioelectronics.2019; 142: 111558. CrossRef
APEX1 Expression as a Potential Diagnostic Biomarker of Clear Cell Renal Cell Carcinoma and Hepatobiliary Carcinomas
Ji-Myung Kim, Min-Kyung Yeo, Jae Lim, In-Sang Song, Kwangsik Chun, Kyung-Hee Kim
Journal of Clinical Medicine.2019; 8(8): 1151. CrossRef
Serum Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) Level as a Potential Biomarker of Cholangiocarcinoma
Doungdean Tummanatsakun, Tanakorn Proungvitaya, Sittiruk Roytrakul, Temduang Limpaiboon, Sopit Wongkham, Chaisiri Wongkham, Atit Silsirivanit, Ongart Somintara, Sakkarn Sangkhamanon, Siriporn Proungvitaya
Biomolecules.2019; 9(9): 413. CrossRef
Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma
Devis Pascut, Caecilia Hapsari Ceriapuri Sukowati, Giulia Antoniali, Giovanna Mangiapane, Silvia Burra, Luca Giovanni Mascaretti, Matteo Rossano Buonocore, Lory Saveria Crocè, Claudio Tiribelli, Gianluca Tell
Oncotarget.2019; 10(3): 383. CrossRef
Apurinic/apyrimidinic endonuclease/redox factor 1 (APE1) alleviates myocardial hypoxia‑reoxygenation injury by inhibiting oxidative stress and ameliorating mitochondrial dysfunction
Jie Hao, Hong Du, Fan Liu, Jing‑Chao Lu, Xiu‑Chun Yang, Wei Cui
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Melissa L. Fishel, Hanyu Xia, Jack McGeown, David W. McIlwain, May Elbanna, Ariel A. Craft, Hristos Z. Kaimakliotis, George E. Sandusky, Chi Zhang, Roberto Pili, Mark R. Kelley, Travis J. Jerde
Molecular Cancer Therapeutics.2019; 18(11): 1947. CrossRef
Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo
Yu Ran Lee, Myoung Soo Park, Hee Kyoung Joo, Ki Mo Kim, Jeryong Kim, Byeong Hwa Jeon, Sunga Choi
Scientific Reports.2018;[Epub] CrossRef
Differential expression of APE1 in hepatocellular carcinoma and the effects on proliferation and apoptosis of cancer cells
Zhipeng Sun, Yubing Zhu, Aminbuhe, Qing Fan, Jirun Peng, Nengwei Zhang
BioScience Trends.2018; 12(5): 456. CrossRef
DNA base excision repair proteins APE‐1 and XRCC‐1 are overexpressed in oral tongue squamous cell carcinoma
Thalita Santana, Melka Coêlho Sá, Edilmar de Moura Santos, Hébel Cavalcanti Galvão, Ricardo D. Coletta, Roseana de Almeida Freitas
Journal of Oral Pathology & Medicine.2017; 46(7): 496. CrossRef
A graphene oxide-based tool-kit capable of characterizing and classifying exonuclease activities
Jayeon Song, Vo Minh Hoa, Jungmin Yoo, Sanghoon Oh, Hyeryeon Im, Daeho Park, Gwangrog Lee
RSC Advances.2017; 7(24): 14917. CrossRef
Apurinic/apyrimidinic endonuclease 1 (APE1) is overexpressed in malignant transformation of salivary gland pleomorphic adenoma
Leorik Pereira Silva, Thalita Santana, Bruno Tavares Sedassari, Suzana Machado de Sousa, Ana Paula Veras Sobral, Roseana de Almeida Freitas, Carlos Augusto Galvão Barboza, Lélia Batista de Souza
European Archives of Oto-Rhino-Laryngology.2017; 274(8): 3203. CrossRef
Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
Fenil Shah, Derek Logsdon, Richard A. Messmann, Jill C. Fehrenbacher, Melissa L. Fishel, Mark R. Kelley
npj Precision Oncology.2017;[Epub] CrossRef
APE1/Ref‐1 knockdown in pancreatic ductal adenocarcinoma – characterizing gene expression changes and identifying novel pathways using single‐cellRNAsequencing
Fenil Shah, Emery Goossens, Nadia M. Atallah, Michelle Grimard, Mark R. Kelley, Melissa L. Fishel
Molecular Oncology.2017; 11(12): 1711. CrossRef
Elevation of Serum APE1/Ref-1 in Experimental Murine Myocarditis
Seon-Ah Jin, Byung-Kwan Lim, Hee Seo, Sun Kim, Kye Ahn, Byeong Jeon, Jin-Ok Jeong
International Journal of Molecular Sciences.2017; 18(12): 2664. CrossRef
APE1 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis
Chun-Ling Yuan, Fan He, Jia-Zhou Ye, Hui-Ni Wu, Jin-Yan Zhang, Zhi-Hui Liu, Yong-Qiang Li, Xiao-Ling Luo, Yan Lin, Rong Liang
Oncotarget.2017; 8(35): 59720. CrossRef
Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker
Sunga Choi, Ju Hyun Shin, Yu Ran Lee, Hee Kyoung Joo, Ki Hak Song, Yong Gil Na, Seok Jong Chang, Jae Sung Lim, Byeong Hwa Jeon
Disease Markers.2016; 2016: 1. CrossRef
Secreted APE1/Ref-1 inhibits TNF-α-stimulated endothelial inflammation via thiol-disulfide exchange in TNF receptor
Myoung Soo Park, Sunga Choi, Yu Ran Lee, Hee Kyoung Joo, Gun Kang, Cuk-Seong Kim, Soo Jin Kim, Sang Do Lee, Byeong Hwa Jeon
Scientific Reports.2016;[Epub] CrossRef
Altered Secretory Activity of APE1/Ref-1 D148E Variants Identified in Human Patients With Bladder Cancer
Yu Ran Lee, Jae Sung Lim, Ju Hyun Shin, Sunga Choi, Hee Kyoung Joo, Byeong Hwa Jeon
International Neurourology Journal.2016; 20(Suppl 1): S30. CrossRef
Dynamic Regulation of APE1/Ref-1 as a Therapeutic Target Protein
Sunga Choi, Hee Kyoung Joo, Byeong Hwa Jeon
Chonnam Medical Journal.2016; 52(2): 75. CrossRef
Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients
Shiheng Zhang, Le He, Nan Dai, Wei Guan, Jinlu Shan, Xueqin Yang, Zhaoyang Zhong, Yi Qing, Feng Jin, Chuan Chen, Yuxin Yang, Hongyi Wang, Laura Baugh, Gianluca Tell, David M. Wilson, Mengxia Li, Dong Wang
Oncotarget.2016; 7(47): 77482. CrossRef

15,036 View
136 Download
57 Web of Science
56 Crossref

First
Prev
Page of 1
Next
Last

Search